$ATOS on their website. Do we know phase -3, NDA dates ? Is this in 2021 or in 2022 Oral Endoxifen We are developing an oral form of endoxifen and we recently reported positive interim results from our Phase 2 study to treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery. A statistically significant (p = 0.031) reduction of about 74% in tumor cell proliferation was achieved over the 22 days of dosing. Proliferation was measured by Ki-67, a recognized standard measurement of breast cancer cell proliferation.
2
2
2 Likes